Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis

Circulation

Volumn 99, Issue 9, 1999, Pages 1141-1146

  Miyazaki, Hiroshi ^a   Matsuoka, Hidehiro ^a   Cooke, John P ^b   Usui, Michiaki ^a   Ueda, Seiji ^a   Okuda, Seiya ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Diabetes mellitus; Dimethylarginine; Hypertension; Risk factors; Smoking

Indexed keywords

ARGININE DERIVATIVE; DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RISK FACTOR; SMOKING;

EID: 0033537633     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.9.1141     Document Type: Article

References (64)

1. Ross R. Rous-Whipple Award Lecture: atherosclerosis: a defense mechanism gone awry. Am J Pathol. 1993;143:987-1002.
2. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwyn AP, Ganz P. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol. 1995;75:71B-74B.
3. Vanhoutte PM. Endothelial dysfunction and atherosclerosis. Eur Heart J. 1997;18(suppl E):E19-E29.
4. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol. 1997;30:325-333.
5. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis. 1997;39:287-324.
6. Cooke JP, Tsao PS. Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb. 1994;14:653-655.
7. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-497.
8. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 1993;91:29-37.
9. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24:1468-1474.
10. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO. Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J Clin Invest. 1995;95:1747-1755.
11. Lüscher TF, Tanner FC, Noll G. Lipids and endothelial function: effects of lipid-lowering and other therapeutic interventions. Curr Opin Lipidol. 1996;7:234-240.
12. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. JAMA. 1984;251:351-374.
13. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984;76(suppl 2A):4-12.
14. Kannel WB. Hypertension, blood lipids and cigarette smoking as co-risk factors for coronary heart disease. Ann N Y Acad Sci. 1978;304:128-139.
15. Levine GN, Keaney JFJ, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med. 1995; 332:512-521.
16. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153-2157.
17. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
18. Ware JA, Heistad DD. Seminars in medicine of the Beth Israel Hospital. Boston: platelet-endothelium interactions. N Engl J Med. 1993;328: 628-635.
19. Stamler JS, Mendelsohn ME, Amarante P, Smick D, Andon N, Davies PF, Cooke JP, Loscalzo J. N-Acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res. 1989;65:789-795.
20. Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis. 1997;129:261-269.
21. Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis. 1995;38: 105-128.
22. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997;48:489-509.
23. G dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl-and galactosyl-delta-hydroxylysine from human urine. J Biol Chem. 1970;245:5751-5758.
24. G dimethylarginine in rats. Arch Biochem Biophys. 1987;252: 526-537.
25. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
26. Fickling SA, Williams D, Vallance P, Nussey SS, Whitley GS. Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia [letter: comment]. Lancet. 1993;342: 242-243.
27. Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local infra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens. 1993;7:193-194.
28. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, Yasukawa H, Iwami G, Okuda S, Imaizumi T. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension. 1997;29:242-247.
29. Bode-Böger SM, Böger RH, Kienke S, Junker W, Frölich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun. 1996;219:598-603.
30. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997;95: 2068-2074.
31. Azuma H, Sato J, Hamasaki H, Sugimoto A, Isotani E, Obayashi S. Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol. 1995;115:1001-1004.
32. Cooke JP, Andon NA, Girerd XJ, Hirsch AT, Creager MA. Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation. 1991;83:1057-1062.
33. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248-1253.
34. Drexler H, Fischell TA, Pinto FJ, Chenzbraun A, Botas J, Cooke JP, Alderman EA. Effect of L-arginine on coronary endothelial function in cardiac transplant recipients: relation to vessel wall morphology. Circulation. 1994;89:1615-1623.
35. Tsao PS, Theilmeier G, Singer AH, Leung LL, Cooke JP. L-Arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb. 1994;14:1529-1533.
36. Wolf A, Zalpour C, Theilmeier G, Wang BY, Ma A, Anderson B, Tsao PS, Cooke JP. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol. 1997; 29:479-485.
37. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation. 1994;89:2176-2182.
38. Wang BY, Candipan RC, Arjomandi M, Hsiun PT, Tsao PS, Cooke JP. Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. J Am Coll Cardiol. 1996;28:1573-1579.
39. Adams MR, Jessup W, Celermajer DS. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol. 1997; 29:491-497.
40. Theilmeier G, Chan J, Zalpour C, Ma A, Anderson B, Wang BY, Wolf A, McEvoy L, Butcher E, Tsao PS, Cooke JP. Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary arginine. Arterioscler Thromb Vasc Biol. 1997;17:3557-3564.
41. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 1992;90:1168-1172.
42. Wang BY, Singer AH, Tsao PS, Drexler H, Kosek J, Cooke JP. Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit. J Am Coll Cardiol. 1994;23:452-458.
43. Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or progression: dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol. 1996;16:44-50.
44. Schwarzacher SP, Lim TT, Wang B, Kernoff RS, Niebauer J, Cooke JP, Yeung AC. Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation. 1997;95:1863-1869.
45. Böger RH, Bode-Böger SM, Brandes RP, Phivthong-ngam L, Böhme M, Nafe R, Mügge A, Frölich JC. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation. 1997;96:1282-1290.
46. Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation. 1997; 96:379-382.
47. World Health Organization. Impaired glucose tolerance and diabetes: WHO criteria. BMJ. 1980;281:1512-1513.
48. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85:447-452.
49. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant. 1996;11: 2449-2452.
50. G-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol. 1997;8:1437-1442.
51. Lopez JP, Narvaez M, Calle A, Rivera J, Jacome P, Ruano C, Nava E. Cyclic guanosine 3′,5′ monophosphate concentrations in pre-eclampsia: effects of hydralazine. Br J Obstet Gynaecol. 1996;103:33-38.
52. Pettersson A, Uggla L, Backman V. Determination of dimethylated arginines in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997;692:257-262.
53. Weidinger FF, McLenachan JM, Cybulsky M, Gordon JM, Rennke HA, Hollenberg NK, Ganz P, Cooke JP. Persistent dysfunction of regenerated endothelium following balloon angioplasty of rabbit iliac artery. Circulation. 1990;81:1667-1679.
54. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
55. G-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol. 1995;269:C750-C756.
56. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb. 1994;14: 753-759.
57. Naruse K, Shimizu K, Muramatsu M, Toki Y, Miyazaki Y, Okumura K, Hashimoto H, Ito T. Prostaglandin H2 does not contribute to impaired endothelium-dependent relaxation and long-term inhibition of nitric oxide synthesis promotes atherosclerosis in hypercholesterolemic rabbit thoracic aorta. Arterioscler Thromb. 1994;14:746-752.
58. Tsao PS, Buitrago R, Chan JR, Cooke JP. Fluid flow inhibits endothelial adhesiveness: nitric oxide and transcriptional regulation of VCAM-1. Circulation. 1996;94:1682-1689.
59. Tsao PS, Wang BY, Guitrago R, Shyy JYJ, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation. 1997;96: 934-940.
60. Craven TE, Ryu JE, Espeland MA, Kahl FR, McKinney WM, Toole JF, McMahan MR, Thompson CJ, Heiss G. Crouse JR. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis: a case-control study. Circulation. 1990;82:1230-1242.
61. Chauhan A, More RS, Mullins PA, Taylor G, Petch MC, Schofield PM. Aging-associated endothelial dysfunction in humans is reversed by L-arginine. J Am Coll Cardiol. 1996;28:1796-1804.
62. G-dimethylarginine in the rabbit. Biochem J. 1976;154:179-184.
63. G-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem. 1989;264:10205-10209.
64. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, Whitley GS, Vallance P. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol. 1996;119:1533-1540.